KR101059579B1 - Stabilized ascorbic acid, humectant and antibacterial agent containing novel pharmaceutical compositions for the treatment of severe dermatitis - Google Patents

Abstract

PURPOSE: A therapeutic agent containing stabilized ascorbic acid, moisturizing agent, and antibacterial agent is provided to treat severe dermatitis. CONSTITUTION: A therapeutic agent for treating severe dermatitis contains ascorbic acid, red ginseng extract, green tea extract, aloe extract, and chlorohexidine in a weight ratio of 1:0.05-50:0.05-50:0.05-50:0.001-0.5. The therapeutic agent also contains 5-80 weight% of excipient. The excipient is selected from the group consisting of propylene glycol, polyethylene glycol, glycerin, sorbitol, alkyl alcohol of 1-12 carbon atoms, EDTA, and citric acid.

Description

Stabilized Ascorbic acid, humectant and antibacterial agent containing novel pharmaceutical compositions for the treatment of severe dermatitis}

The present invention relates to a therapeutic agent for skin diseases containing stabilized ascorbic acid, a moisturizing agent and an antimicrobial agent, and more specifically, ascorbic acid, red ginseng extract, green tea leaf extract, aloe extract and chlorhexidine as an active ingredient. The present invention relates to a skin disease treatment agent.

Ascorbic acid helps to create healthy and attractive skin and promotes the production of collagen, an ingredient that prevents wrinkles and premature aging, and helps maintain young skin for a long time. Ascorbic acid is also a powerful antioxidant and an essential component of multivitamins. However, when taken orally, the recommended daily dose for adults is about 70 mg. When taken in excess, it is excreted in the urine, but so-called mega therapy can cause side effects such as urolithiasis and kidney stones.

However, when ascorbic acid is used as an external preparation, there is no side effect, so it has an advantage of absorbing a large amount at a time over a wide area. Ascorbic acid, however, is a water-soluble vitamin, well soluble in water, very unstable in water, oxygen and heat, and very unstable in contact with metal ions such as iron and copper. Therefore, in order to be administered as an external preparation, it is necessary to secure chemical stability first, and it is essential to design and manufacture a preparation for good absorption. Therefore, if the chemical stability of ascorbic acid can be secured, it is also possible to use megatherapy through the external preparation form, and thus it can be utilized in various fields, thus securing stability in ascorbic acid is a very important issue. Therefore, if a chemically stabilized ascorbic acid formulation is developed and used as a therapeutic agent for skin diseases, it may be used in various skin disease treatment fields.

Currently, in the case of atopic dermatitis, a good therapeutic agent has not been developed, and antihistamines and steroid creams are temporarily used for temporary moisturizing and itch relief. However, this is only a temporary improvement of the symptoms, and in the case of steroids also had the problem of causing serious side effects such as promoting skin aging, redness, weakened immunity. Examples of the use of ascorbic acid for skin diseases are disclosed in US Pat. No. 5,646,190, etc., but this technique also did not solve the stability problem of ascorbic acid, and the formulation formed therefrom was also unstable to use as it is. Therefore, it is urgently needed to secure the stability of ascorbic acid and develop it as an agent that can be used to treat skin diseases.

Accordingly, the present inventors have conducted research and efforts to overcome the problems of the prior art as described above, as a result of preparing a formulation comprising chlorhexidine as an acolic acid extract, green tea leaf extract, aloe extract as a moisturizing agent and chlorhexidine as an antimicrobial agent, which has not been previously secured. As a result, the present invention was completed by developing a formulation having excellent effects on treating damaged skin infections, as well as securing stability of ascorbic acid and further maximizing antibacterial and moisturizing effects.

Accordingly, an object of the present invention is to provide a therapeutic agent that exhibits an excellent effect in treating severe skin diseases.

In order to achieve the above object, the present invention provides a therapeutic agent for skin diseases comprising ascorbic acid, red ginseng extract, green tea leaf extract, aloe extract and chlorhexidine as an active ingredient.

The therapeutic agent for skin diseases according to the present invention is a formulation containing ascorbic acid, red ginseng extract, green tea leaf extract, aloe extract and chlorhexidine as active ingredients, and it is a skin-friendly, ingredient having no side effects as a main component. It is safe because it is configured, and a high dose of drug can be absorbed quickly in the affected area, so a rapid therapeutic effect can be expected. In addition, the stability is ensured and used as a therapeutic agent for skin diseases that replaces steroids, antihistamines, antibiotics, and moisturizers, which have been used to treat conventional insect bites, atopic dermatitis, contact dermatitis and subsequent secondary infections. It is expected to be able. In addition, it is expected to have a great impact on the development of the pharmaceutical industry and the promotion of public health, since it is possible to ensure long-term distribution because it is guaranteed during manufacturing as a medicine.

The therapeutic agent for skin diseases according to the present invention includes ascorbic acid, red ginseng extract, green tea leaf extract, aloe extract and chlorhexidine as active ingredients.

Hereinafter, the components of each of the therapeutic agents for skin diseases of the present invention will be described in more detail.

Ascorbic acid of the present invention is a water-soluble vitamin that is involved in the synthesis of collagen, which gives skin moisture and elasticity, prevents skin aging, and removes blemishes and freckles with powerful antioxidants, and helps the absorption of iron in the small intestine. It is a vitamin involved in the enhancement of carnitine biosynthesis and immune function. It also acts as an antagonist against histamine causing allergic reactions in the human body and can be used for various skin diseases.

Ascorbic acid may be used ascorbic acid or ascorbic acid derivatives, the ascorbic acid derivatives, for example, sodium ascorbylphosphate (Sodium ascorbylphosphate), magnesium ascorbyl phosphate (Magnesium ascorbyl phosphate), calcium as Calcium ascorbylphosphate, Ascorbic acid polypeptide, Ethyl ascorbyl ether, Ascorbyl dipalmitate, Ascorbyl palmitate, Ascorbyl palmitate, Ascorbyl palmitate, Ascorbyl palmitate Ascorbyl stearate, Ascorbyl glucoside, Ascorbyl ethylsilanol pectinate, and the like can be used. You may use the said ascolic acid derivative in combination of 2 or more type.

The red ginseng extract of the present invention can be prepared by concentrating the liquid obtained by extracting red ginseng obtained by steaming ginseng with hot water. The red ginseng extract may be purchased on the market. Red ginseng extract boosts immunity and helps relieve disease and stress. In the present invention, by being used with ascorbic acid plays a role of increasing the strong antioxidant effect of ascorbic acid. Preferably, it is recommended to use domestic 6-year-old red ginseng extract concentrate or domestic 6-year-old fermented red ginseng extract concentrate, and three steamed three times after sun-dried three times three width (三 蒸 三 曝) to use. .

The green tea leaf extract of the present invention may be obtained by boiling green tea leaf in purified water, filtering and concentrating it, or may purchase and use a commercially available one. Green tea leaf extract is a powerful antioxidant when used with the ascorbic acid of the present invention increases the potent antioxidant effect of ascorbic acid, catechin, the main component of the green tea leaf shows a synergistic effect to increase the stability of ascorbic acid.

The present invention uses aloe extract, which is a natural moisturizer, to relieve the symptoms of skin diseases such as atopic dermatitis in addition to the ascorbic acid, red ginseng extract and green tea leaf extract, and to prevent the dryness of damaged skin, and also to invade through damaged skin. It is noted that the produced metabolite further exacerbates the symptoms of skin diseases such as atopic dermatitis. To prevent this, chlorhexidine, a relatively antibacterial and powerful antimicrobial agent, is used.

The aloe extract of the present invention may be prepared by concentrating the aloe, and the concentration may use various methods known in the art. Alternatively, a commercially available product may be purchased and used.

The chlorhexidine of the present invention is not limited, but may preferably be used in the form of chlorhexidine or chlorhexidine, and the salt of chlorhexidine, Chlorhexidine dihydrochloride, Chlorhexidine diacetate, Chlorhexidine diacetate Gluconate (Chlorhexidine digluconate) and the like can be used.

In the present invention, the weight ratio of the ascorbic acid, red ginseng extract, green tea leaf extract, aloe extract and chlorhexidine is not limited, but preferably in the order listed above 1: 0.05 to 50: 0.05 to 50: 0.05 to 50: 0.001 It is mixed so that it becomes -0.5, More preferably, it mixes so that it may become a weight ratio of 1: 0.1-10: 0.1-10: 0.1-10: 0.001-0.1. The mixing ratio may be configured differently depending on the formulation to be made later.

When the weight ratio of the red ginseng extract is less than 0.05 compared to the 1 weight ratio of ascorbic acid, there may be a problem that the intake of the active pharmacological components of red ginseng decreases the functionality, the weight ratio exceeds 50 compared to the 1 weight ratio of ascorbic acid In this case, there may be a problem in that the intake of ascorbic acid is relatively low, thereby decreasing the functionality and increasing the manufacturing cost.

When the weight ratio of the green tea leaf extract is less than 0.05 compared to the 1 weight ratio of the ascorbic acid, there may be a problem that the amount of effective pharmacological components of the green tea leaf decreases the functionality and the stability of the ascorbic acid is weakened, When the weight ratio exceeds 50 ascorbic acid 1 weight ratio, there may be a problem that the intake of ascorbic acid is relatively low, thereby weakening the functionality.

When the weight ratio of the aloe extract is less than 0.05 compared to 1 weight ratio of ascorbic acid, there is a problem in that a moisturizing effect is lowered and skin diseases such as atopic dermatitis worsen, and if the weight ratio exceeds 50 compared to 1 weight ratio of ascorbic acid, Intake of ascorbic acid may cause a problem of weakened functionality.

When the weight ratio of the chlorhexidine is less than 0.001 to the weight ratio of ascorbic acid, there is a problem that the secondary damage caused by these bacteria is accelerated due to the small amount of antimicrobial activity against the bacteria invading through the damaged skin, and the weight ratio of the ascorbic acid 1 If it exceeds 0.5 by weight, it is not preferable in terms of economics, so it is preferable to maintain the above range.

The therapeutic agent for skin diseases of the present invention can be prepared and used as a stock solution containing the active ingredients.

The preparation of the stock solution may further include one or more excipients in addition to the active ingredients listed above, and the excipient may be freely selected and used without being limited to the type depending on the composition of the stock solution to be made. Excipients that can be used include propylene glycol, polyethylene glycol (PEG), glycerin (Glycerine), sorbitol (Sorbitol), alkyl alcohols having 1 to 12 carbon atoms, chelating agents EDTA, citric acid, etc. Can be mixed. The propylene glycol as an excipient, a polyethylene glycol (PEG), glycerin or the case of using the sorbitol hydroxyl radical (OH ^-) and serves to protect the asbestos Colvin acid from, and to improve the stability of asbestos Colvin acid, a chelating agent When phosphorus EDTA is used together, EDTA combines with heavy metals to maintain the stability of ascorbic acid.

The amount of the active ingredient including ascorbic acid, red ginseng extract, green tea leaf extract, aloe extract and chlorhexidine in the stock solution is preferably included in an amount of 0.1 to 70% by weight, preferably 10 to 30% by weight based on the total composition, and an excipient Is preferably included in the range of 5 to 80% by weight, preferably 10 to 30% by weight. In addition to the active ingredient and excipient, purified water may be prepared to prepare 100% by weight of purified water.

In the preparation or storage of the stock solution of the present invention, a glass container (Pyrex) or a stainless steel container is preferably used to prevent contact with a metal such as copper (Cu) or iron (Fe), which is a catalyst for promoting decomposition of ascorbic acid. It is good to use When using the container there is an advantage that can maintain the stability of ascorbic acid for a long time.

The therapeutic agent for skin diseases according to the present invention is used for all kinds of skin diseases, but in particular, it can be effectively used for contact dermatitis and insect bites such as severe atopic dermatitis, eczema and the like.

In addition, by using the stock solution prepared by containing the ascorbic acid, red ginseng extract, green tea leaf extract, aloe extract and chlorhexidine of the present invention, it can be prepared as an external preparation of various formulations and used as a therapeutic agent for skin diseases.

The external preparation of the present invention may be prepared in any formulation conventionally prepared in the art, for example, external preparations, emulsions, suspensions, pastes, gels, creams, lotions, soaps, oils, powders, waxes, It may be formulated as a spray, etc., but is not limited thereto.

For example, when the formulation of the present invention is a cream, an additive is a liquid diluent such as ethyl alcohol, purified water or propylene glycol, lanolin oil, acetylated lanolin alcohol, cetyl alcohol, biswax, BHT, alkylparabens. And the like can be used. When the formulation of the present invention is a lotion, as an additive propylene glycol, methyl Gluceth-10, carbomer 941, lanolin alcohol, mineral oil, cetyl alcohol, Solulan C-24, stearic acid, Glyceryl stearate, water, alkyl parabens and the like can be used. When the formulation of the present invention is in the form of a gel, alkylene glycol, water, carbomer 940 or the like may be used as an additive. When the formulation of the present invention is a spray, a liquid diluent such as water, ethyl alcohol or propylene glycol may be used as an additive.

Hereinafter, the present invention is described as follows to explain the present invention in more detail, but the present invention is not limited to the examples.

Manufacturing example : Green tea leaf extract  Produce

1Kg of Boseong-gun, Jeonnam green tea leaves were placed in 2 liters of purified water (H ₂ O), boiled at 100 ° C. for 3 hours, and then filtered through a membrane filter. Thereafter, the filtrate was concentrated with a vacuum condenser to prepare green tea leaf extract.

Example  1: stabilized Ascorbic Acid Of the therapeutic stock solution containing antiseptics, moisturizers and antibacterial agents

9.41 g of ascorbyl palmitate (manufactured by Aldrich Co., Ltd.), domestic ginseng extract 4g (Gumsan Ginseng Agricultural Co., Ltd.), 6 g of Korean ginseng extract, 4 g of green tea leaf extract of the above example, 30 g of propylene glycol, ethyl alcohol (ethyl alcohol) alcohol) 25ml, glycerin (glycerine) 30g and sorbitol (sorbitol) 5g was mixed. In the mixture, 100 mg of EDTA (disodium) and 20 mg of chlorhexidine were dissolved in 10 ml of purified water and 2 g of aloe extract (Kim Jung Moon Aloe) was mixed. Then, purified water was added to make the total amount 100g.

Example  2: stabilized Ascorbic Acid Of the therapeutic stock solution containing antiseptics, moisturizers and antibacterial agents

9.41 g of ascorbyl palmitate (manufactured by Aldrich, Inc.), 6 g of red ginseng extract (4 g of Geumsan Ginseng Agricultural Co., Ltd.), 4 g of green tea leaf extract of the above example, 30 g of propylene glycol, ethyl alcohol (ethyl alcohol) 25 ml, 20 g of glycerine and 5 g of sorbitol were mixed. In the mixture, 100 mg of EDTA (disodium) and 20 mg of chlorhexidine were dissolved in 10 ml of purified water and 2 g of aloe extract (Kim Jung Moon Aloe) was mixed. Then, purified water was added to make the total amount 100g.

Example  3: stabilized Ascorbic Acid Of the therapeutic stock solution containing antiseptics, moisturizers and antibacterial agents

9 g of red ginseng extract (Ascorbyl palmitate, manufactured by Aldrich) 6 g of red ginseng extract (Gumsan ginseng cooperatives), 4 g of green tea leaf extract of the above example, 25 g of PEG400 (manufactured by Aldrich), isopropyl alcohol (Isopropyl alcohol) ) 25ml, glycerin (glycerine) 30g and sorbitol (g) 7g was mixed. In the mixture, 100 mg of EDTA (disodium) and 20 mg of chlorhexidine were dissolved in 10 ml of purified water and 2 g of aloe extract (Kim Jung Moon Aloe) was mixed. Then, purified water was added to make the total amount 100g.

※ In the case of PEG400 was used to remove the peroxide (drying) through a heating mantle (heating mantle).

Example  4: cream Cream Manufacturing

One of the stock solutions of Examples 1 to 3 may be arbitrarily selected, and 25 g may be used. In this example, the stock solution of Example 1 was used. This stock solution was placed in a stainless steel No. 316 preparation tank (tank) to prepare the following [Composition A]. After adding [Composition C] to the mixture therein, [Composition B] was added and all the mixtures were mixed evenly with a high speed mixer to prepare a cream.

[Production of Composition A]

1. Stock Solution of Example 1 ... 25 g

2.Propylene Glycol ............... 24.5g

3. Citric Acid ..................... 0.1g

4. Purified water ......................................... 3.35g

1 to 4 were mixed to prepare [Composition A].

[Production of Composition B]

Lanolin oil ........................... 30.0g

2. Cetyl alcohol ......................... 4.5g

3. Stearyl alcohol ......... 2.0g

4. Beeswax ......................... 2.0g

5.BHT (Butylate hydroxy toluene) ..... 2.0g

The materials of 1 to 5 were mixed and then melted by heating to 80 ° C. and evenly mixed. Then it was cooled to 30 ℃ to prepare [Composition B].

[Production of Composition C]

1.Methylparaben ........................ 0.3g

2. Propylparaben ..................... 0.25g

3.Ethyl alcohol ............... 10ml

4. Purified Water ......................................... 5ml

5. Aloe Extract ........................................ 2g

6. Chlorhexidine .................................... 20ml

20 ml of chlorhexidine is dissolved in 5 ml of purified water, and 2 g of aloe extract is mixed therein. Separately, methyl paraben and propyl paraben were dissolved in 10 ml of ethyl alcohol, and the two solutions were slowly added and uniformly mixed to prepare [Composition C].

Example  5: lotion ( Lotion Manufacturing

One of the stock solutions of Examples 1 to 3 may be arbitrarily selected, and 25 g may be used. In this example, the stock solution of Example 1 was used. This stock solution was placed in a stainless steel No. 316 preparation tank (tank) to prepare the following [Composition A]. This was mixed with the following [Composition B]. Thereafter, a mixture of [Composition C] and [Composition D] was added thereto and mixed with a high speed mixer to prepare a lotion agent.

[Production of Composition A]

1. Stock Solution of Example 1 ... 25 g

2.Propylene glycol ..... 30g

3.Lanolin alcohol ........................ 4g

[Composition A] was prepared by mixing the above 1 to 3 using a high speed mixer.

[Production of Composition B]

Cetyl alcohol ..................... 1.0g

2.Solulan C-24 ............. 0.3g

3. Stearic acid ......................... 3.0g

4.Glyceryl stearate ......... 2.0g

The 1-4 materials were mixed and then melted by heating to 80 ° C. Then it was cooled to 30 ℃ to prepare a [Composition B].

[Production of Composition C]

Methyl gluceth-10 5.0 g

2. Purified water .............. 20.0 ml

[Composition C] was prepared by mixing the materials of 1-2.

[Production of Composition D]

1.Methylparaben ........................ 0.3g

2. Propylparaben ..................... 0.25g

3. Purified water ..................... 8.0g

4. Aloe Extract .................................... 2.0g

5.Ethyl alcohol ............... 10ml

1 and 2 were dissolved in ethyl alcohol, and purified water and aloe extract were added thereto, and mixed evenly to prepare [Composition D].

Example  6: Gel  Produce

One of the stock solutions of Examples 1 to 3 may be arbitrarily selected, and 25 g may be used. In this example, the stock solution of Example 1 was used. 30 g of propylene glycol and 30 g of purified water were added to the stock solution, followed by mixing. After slowly dissolving 2.0 g of Carbomer 940, purified water was added to make 100 g, thereby preparing a gel.

Example  7: Spray Spray Manufacturing

One of the stock solutions of Examples 1 to 3 may be arbitrarily selected, and 25 g may be used. In this example, the stock solution of Example 1 was used. 30 g of propylene glycol and 10 g of ethyl alcohol were added to the stock solution, mixed with purified water, and then mixed with 100 g of purified water to prepare a spray agent.

Test Example  1: Stability test (stock form)

In order to test the stability of the stock solutions of Examples 1 to 3 according to the present invention, the test was carried out using an aqueous solution of ascorbic acid that does not contain other active ingredients as a control. The stability of ascorbic acid in each stock solution prepared by the method of Examples 1 to 3 at a temperature of 40 ° C. and a relative humidity of 60% was tested. As a control, 100 g of ascorbic acid aqueous solution (1 wt% aqueous solution) containing no other active ingredient was used. Residual amounts of ascorbic acid were measured after the initial stage (day 1), after 1 month, after 2 months and after 3 months, respectively, and the assay was determined by USP XXX II (HPLC method).

The HPLC method was performed using a PolySep GFC-P Series, Shodex RSpak DM-614, 6 mm x 150 mm column, and as a mobile phase, 15.6 g of dibasic sod. Phosphate dissolved in 200 ml of water and potassium basic phosphate (monobasic pot). 12.2 g of phosphate was used, and the pH was maintained at a value of 2.5 ± 0.05 as a buffer solution, the flow rate was 0.6 ml / min, and the detector was UV A detector (wavelength: 254 nm) was used.

The results obtained by the test are shown in Table 1 below.

Ascorbic acid  Residual amount (%) Early 1 month later 2 months later 3 months later Control group 100.0 63.5 35.2 10.3 Example 1 100.0 99.3 99.2 99.1 Example 2 100.0 99.7 99.5 98.9 Example 3 100.0 99.5 99.4 98.4

In the light of the above experimental results, the existing ascorbic acid composition as a control group was found to have a very low stability, so that the residual rate dropped to 63.5% after one month. On the other hand, the stock solution prepared by Examples 1 to 3 of the present invention can be seen that ascolic acid remains up to 99.1% after 3 months and its stability is very excellent. In the case of pharmaceuticals, the commercial use value is very high in view of the commercial availability only when a long period of stability is maintained in the manufacturing, storage and distribution process.

Test Example  2: Stability Test (Formulation Form)

In order to compare the stability of the formulations prepared by the present invention with conventional products, the stability of ascorbic acid in each formulation prepared by the method of Examples 4 to 7 was measured under refrigeration conditions (2 ° C.) and room temperature conditions. (25 ° C.) and harsh conditions (40 ° C., relative humidity 60%). As a control, 25 g of ascorbic acid aqueous solution (1 wt% aqueous solution) containing no other active ingredient was prepared in the same manner as described in Examples 4 to 7 except that the stock solution of Example 1 was used instead. Formulations were used. The residual amount of ascorbic acid was measured after the initial stage (1 day), after 1 month, after 2 months and after 3 months, respectively, and the analysis was performed using the HPLC method under the same conditions as in Test Example 1.

The results obtained by the above experiments are shown in Table 2 below.

Ascorbic acid  Residual amount (%) Early 1 month later 2 months later 3 months later cream Control group (severe) 100.0 64.7 32.3 9.5 Example 4 (Refrigeration) 100.2 100.2 99.5 99.3 Example 4 (room temperature) 100.1 99.1 98.7 98.0 Example 4 (severe) 100.3 97.8 97.5 97.0 Lotion Control group (severe) 100.0 62.9 30.5 8.2 Example 5 (Refrigeration) 100.0 100.0 99.6 99.4 Example 5 (room temperature) 100.1 99.2 98.9 98.2 Example 5 (severe) 100.2 98.0 97.7 97.2 Gel Control group (severe) 100.0 60.4 29.2 7.5 Example 6 (Refrigeration) 100.0 99.8 99.2 99.0 Example 6 (room temperature) 100.1 99.1 98.8 97.9 Example 6 (severe) 100.0 97.6 97.1 97.0 spray Control group (severe) 100.0 59.3 22.5 6.8 Example 7 (Refrigeration) 100.2 99.5 99.3 99.0 Example 7 (room temperature) 100.1 99.2 98.5 98.2 Example 7 (severe) 100.1 97.8 97.4 97.1

As can be seen from the above experiment, the formulation of the present invention was found to be very stable under refrigerated or room temperature conditions and decomposed only about 3% even under severe conditions.

In view of the above results, the composition of the present invention is very stable even under severe conditions, and when it is commercialized, 95% (Label claim) or more after 3 months under US FDA standards (40 ° C, 60% RH (relative humidity) conditions). 2 years of validity can be granted.

Test Example  3: simplified clinical trial

A simple clinical trial was conducted to test the efficacy of the therapeutic agent for skin diseases according to the present invention. Liver trials were conducted on a total of 20 patients with severe atopic dermatitis, including children under 5 years of age and patients in their early 20s. In this test, the cream of Example 4 was used in the formulation of the present invention, and a commercial 0.1% dexamethasone cream (Dexamethazone propionate cream) was used as a control. Affected area 10 cm ² After 100 mg of the drug was applied to the affected area, itching, keratinization, skin redness and infection associated with atopic dermatitis were observed. The test period was one week.

The results obtained by the above experiments are shown in Table 3 below.

Atopic dermatitis division When using the cream of Example 4 0.1% Dexamethasone Cream One All four symptoms improved Only 2 symptoms improved (itching, redness improvement) 2 All four symptoms improved Only 2 symptoms improved (itching, redness improvement) 3 All four symptoms improved Only 2 symptoms improved (itching, redness improvement) 4 All four symptoms improved Only one symptom is improved (improved itching) 5 All four symptoms improved Only 2 symptoms improved (itching, redness improvement) 6 All four symptoms improved Only 2 symptoms improved (itching, redness improvement) 7 All four symptoms improved Only 2 symptoms improved (itching, redness improvement) 8 All four symptoms improved Only one symptom is improved (improved itching) 9 All four symptoms improved Only one symptom is improved (improved itching) 10 All four symptoms improved Only 2 symptoms improved (itching, redness improvement) 11 All four symptoms improved Only 2 symptoms improved (itching, redness improvement) 12 All four symptoms improved Only 2 symptoms improved (itching, redness improvement) 13 All four symptoms improved Only one symptom is improved (improved itching) 14 All four symptoms improved Only 2 symptoms improved (itching, redness improvement) 15 All four symptoms improved Only 2 symptoms improved (itching, redness improvement) 16 All four symptoms improved Only 2 symptoms improved (itching, redness improvement) 17 All four symptoms improved Only 2 symptoms improved (itching, redness improvement) 18 All four symptoms improved Only 2 symptoms improved (itching, redness improvement) 19 All four symptoms improved Only 2 symptoms improved (itching, redness improvement) 20 All four symptoms improved Only one symptom is improved (improved itching)

※ The improvement of atopic dermatitis was determined based on itching, keratinization, redness and infection, and all 4 symptoms improved, 3 improved symptoms 3, 2 improved symptoms 2, 1 improved symptoms 1 Represented by.

As can be seen from the results of the above clinical trials, steroid preparations such as dexamethasone are mainly used because there is no direct treatment for atopic dermatitis, but this only improves some symptoms such as itching and skin redness, It does not improve symptoms at all, but rather can cause a decrease in immunity, which can make the infection worse. The therapeutic agent for skin diseases according to the present invention includes ascorbic acid and green tea leaf extract, which are powerful antioxidants, red ginseng extract to enhance immunity, and aloe extract having moisturizing ingredients necessary for the treatment of atopic dermatitis, and infection caused by weakened skin. Chlorhexidine can be used as atopic dermatitis as well as eczema, insect bite, contact dermatitis, etc., it can be seen that it can be a therapeutic drug for skin diseases.

Claims (6)

Ascolic acid, red ginseng extract, green tea leaf extract, aloe extract and chlorhexidine as an active ingredient, a cosmetic composition for preventing or improving atopic dermatitis, characterized in that it comprises.
The cosmetic composition according to claim 1, wherein the weight ratio of ascorbic acid, red ginseng extract, green tea leaf extract, aloe extract and chlorhexidine is 1: 0.05-50: 0.05-50: 0.05-50: 0.001-0.5.
The cosmetic composition according to claim 1, comprising at least one selected from the group consisting of propylene glycol, polyethylene glycol, glycerin, sorbitol, alkyl alcohols having 1 to 12 carbon atoms, EDTA, and citric acid as excipients.
According to claim 3, wherein the excipient cosmetic composition, characterized in that contained in 5 to 80% by weight.
delete The cosmetic composition according to claim 1, wherein the cosmetic composition is formulated in the form of external solution, emulsion, suspension, paste, gel, cream, lotion, soap, oil, powder, wax or spray.